Navigation Links
NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
Date:1/12/2009

gh eight, compared with patients who received the control patch. Reduction in pain during Weeks two through twelve was also significantly greater in patients treated with Qutenza. Qutenza was generally well tolerated. The most common adverse effects were related to local, application site reactions and treatment-associated pain.

Anthony DiTonno, President and CEO, commented, "Current PHN treatment options have limitations that we believe present an opportunity for Qutenza to address. In addition to the potential for a long duration of effect, Qutenza acts locally, at the pain site, as opposed to through the central nervous system, and has the potential to manage pain resulting from PHN without causing some of the common side effects associated with currently available systemic treatment options. With both our NDA and MAA currently under review, we look forward to regulatory decisions on these applications and the potential for subsequent commercial launches of Qutenza in both the United States and European Union."

The first author of the publication, Miroslav Backonja M.D., Professor of Neurology, Anesthesiology and Rehabilitation Medicine at the University of Wisconsin School of Medicine, stated, "The results from the Phase 3 C116 study of Qutenza in patients with PHN showed that a single 60-minute application of Qutenza has the potential to provide targeted pain management for up to 12 weeks. I am very glad that Qutenza has the potential upon approval to offer our patients a significant improvement to the current treatment options for PHN."

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
2. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
3. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
4. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
5. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... NEW YORK, Nov. 11 Pulmo BioTech Inc. (OTC ... early experimental results have indicated that its PulmoBind(TM) product ... and follow-up of many conditions that affect the physical ... results, if confirmed by further experiments, would broaden the ...
Cached Medicine Technology:Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 2Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 3Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 4
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive survey ... Research and Policy Analysis show widespread support for the U.S. Affordable Care Act ... strongly agreed that the controversial law passed in 2010 had “more good than ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... study by the University of the Basque Country (UPV/EHU) ... emotional differences between the sexes and generations in terms ... than children, while women are better at forgiving than ... values, because it shows us what reasons people have ...
... CKD have an increased risk of adverse outcomes. Despite ... overt nephropathy develop End-Stage Renal Disease (ESRD) and/or succumb ... and ESRD may confound the estimates of risk for ... University of Helsinki, University Hospital of Helsinki and Folkhlsan ...
... By Alan Mozes HealthDay Reporter , ... bike-only tracks that are physically separated from street traffic ... vehicles, a new study finds. "We found that ... bicycling on cycle tracks, compared with bicycling in parallel ...
... Most people know that exercise is important ... and obesity rates are at all-time highs and ... study, University of Missouri researchers found that healthy ... significantly increased their physical activity levels. Conversely, interventions ...
... This release is available in French . ... speech experts will take centre stage in discussions on the ... of the American Association for the Advancement of Science in ... has been a driving force in revealing the unique window ...
... Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality ... radiation therapy in treating bone metastases. The guideline will ... OncologyBiologyPhysics , an official journal of ASTRO. Bone metastases ... bone. They can lead to debilitating effects including pain, ...
Cached Medicine News:Health News:Women are better at forgiving 2Health News:Competing risks analysis highlights new targets in preventing ESRD and death of diabetics 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 3Health News:To increase physical activity, focus on how, not why 2Health News:Canadian brainpower at AAAS in Washington 2Health News:ASTRO publishes palliative radiotherapy for bone metastases guideline 2
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
Medicine Products: